IL280029A - Ror-1 specific chimeric antigen receptors and uses thereof - Google Patents

Ror-1 specific chimeric antigen receptors and uses thereof

Info

Publication number
IL280029A
IL280029A IL280029A IL28002921A IL280029A IL 280029 A IL280029 A IL 280029A IL 280029 A IL280029 A IL 280029A IL 28002921 A IL28002921 A IL 28002921A IL 280029 A IL280029 A IL 280029A
Authority
IL
Israel
Prior art keywords
ror
chimeric antigen
antigen receptors
specific chimeric
specific
Prior art date
Application number
IL280029A
Other languages
English (en)
Hebrew (he)
Inventor
Changhung Chen
Vinodhbabu Kurella
Rutul R Shah
Cheryl G Bolinger
Amy Wesa
Original Assignee
Precigen Inc
Changhung Chen
Vinodhbabu Kurella
Rutul R Shah
Cheryl G Bolinger
Amy Wesa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precigen Inc, Changhung Chen, Vinodhbabu Kurella, Rutul R Shah, Cheryl G Bolinger, Amy Wesa filed Critical Precigen Inc
Publication of IL280029A publication Critical patent/IL280029A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL280029A 2018-07-10 2021-01-07 Ror-1 specific chimeric antigen receptors and uses thereof IL280029A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862696075P 2018-07-10 2018-07-10
PCT/US2019/041213 WO2020014366A1 (en) 2018-07-10 2019-07-10 Ror-1 specific chimeric antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
IL280029A true IL280029A (en) 2021-03-01

Family

ID=69141807

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280029A IL280029A (en) 2018-07-10 2021-01-07 Ror-1 specific chimeric antigen receptors and uses thereof

Country Status (11)

Country Link
US (2) US12275772B2 (https=)
EP (1) EP3820484A4 (https=)
JP (2) JP2021530217A (https=)
KR (1) KR20210043562A (https=)
CN (1) CN112714769A (https=)
AU (1) AU2019301147B2 (https=)
CA (1) CA3105816A1 (https=)
IL (1) IL280029A (https=)
SG (1) SG11202100205UA (https=)
WO (1) WO2020014366A1 (https=)
ZA (1) ZA202100391B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3697438A4 (en) * 2017-10-18 2021-08-18 Intrexon Corporation POLYPEPTIDE COMPOSITIONS WITH SPACERS
EP3820484A4 (en) 2018-07-10 2022-05-04 Precigen, Inc. ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF
US20210388317A1 (en) * 2018-10-26 2021-12-16 Shinshu University High-efficiency method for producing genetically modified cells
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
IL296511A (en) 2020-03-20 2022-11-01 Lyell Immunopharma Inc Novel recombinant cell surface markers
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN113584083A (zh) * 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
WO2022097068A1 (en) 2020-11-05 2022-05-12 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
TW202233662A (zh) * 2020-12-31 2022-09-01 大陸商亘喜生物科技（上海）有限公司 膜融合蛋白及其在免疫細胞中的應用
MX2023008115A (es) * 2021-01-11 2023-09-11 Precigen Inc Terapia con receptores quiméricos.
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
US20240415883A1 (en) * 2021-02-01 2024-12-19 The Regents Of The University Of California Treatment of neuroendocrine cancers
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
JP2024508597A (ja) * 2021-03-09 2024-02-28 四川科倫博泰生物医薬股▲フン▼有限公司 Ｒｏｒ１結合タンパク質及びその用途
MX2024002172A (es) * 2021-08-18 2024-07-10 Univ Pennsylvania Composiciones y métodos para receptores de antígenos quiméricos específicos para receptores de células b.
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
IL316226A (en) * 2022-05-24 2024-12-01 Caribou Biosciences Inc Anti-ror1 antibody and ror1-targeting engineered cells
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN118206620A (zh) * 2022-12-09 2024-06-18 上海细胞治疗集团股份有限公司 一种多肽标签及其应用
CN116284246B (zh) * 2022-12-12 2025-11-14 江苏三联生物工程股份有限公司 信号肽、核酸片段、重组表达载体、宿主细胞及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025194140A1 (en) * 2024-03-15 2025-09-18 Port Therapeutics, Inc. Thermally controlled gene expression and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
AU734051B2 (en) 1996-04-05 2001-05-31 Salk Institute For Biological Studies, The Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
AU738494B2 (en) 1997-07-10 2001-09-20 Salk Institute For Biological Studies, The Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US9242014B2 (en) * 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3828205A1 (en) * 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
DK3252076T3 (da) * 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
SG10201600912SA (en) * 2011-03-04 2016-03-30 Intrexon Corp Vectors conditionally expressing protein
EA033110B1 (ru) * 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
EP2906599B1 (en) * 2012-10-12 2019-07-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP2017501712A (ja) 2013-12-18 2017-01-19 イントレキソン コーポレーション 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用
KR102048855B1 (ko) * 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
JP2017522893A (ja) * 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
SG11201702295UA (en) 2014-09-22 2017-04-27 Intrexon Corp Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
JP6865688B2 (ja) * 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
CN108137669B (zh) * 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
SG11201802912PA (en) 2015-10-10 2018-05-30 Intrexon Corp Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
SG11201810640RA (en) * 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
AU2017368248A1 (en) * 2016-11-30 2019-06-06 Intrexon Corporation Steroid administration and immunotherapy
CN110291200B (zh) * 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
KR20190102259A (ko) * 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
EP3635132A4 (en) 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
EP3697438A4 (en) * 2017-10-18 2021-08-18 Intrexon Corporation POLYPEPTIDE COMPOSITIONS WITH SPACERS
SG11202009697RA (en) 2018-03-30 2020-10-29 Univ Geneve Micro rna expression constructs and uses thereof
EP3820484A4 (en) 2018-07-10 2022-05-04 Precigen, Inc. ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF

Also Published As

Publication number Publication date
AU2019301147B2 (en) 2026-03-26
AU2019301147A1 (en) 2021-01-21
KR20210043562A (ko) 2021-04-21
US20260035432A1 (en) 2026-02-05
JP2021530217A (ja) 2021-11-11
EP3820484A4 (en) 2022-05-04
CN112714769A (zh) 2021-04-27
EP3820484A1 (en) 2021-05-19
SG11202100205UA (en) 2021-02-25
US20210177902A1 (en) 2021-06-17
JP2024073449A (ja) 2024-05-29
US12275772B2 (en) 2025-04-15
CA3105816A1 (en) 2020-01-16
WO2020014366A1 (en) 2020-01-16
ZA202100391B (en) 2025-05-28

Similar Documents

Publication Publication Date Title
IL280029A (en) Ror-1 specific chimeric antigen receptors and uses thereof
IL279979A (en) Chimeric antigen receptors with bcma specificity and uses thereof
EP3999550A4 (en) ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
IL281098A (en) Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
IL283734A (en) Chimeric antigen receptors and car-t cells and methods of use
PT3802608T (pt) Anticorpos anti-cd3 e utilizações destes
IL280033A (en) Uses of anti-bcma chimeric antigen receptors
IL275619A (en) Amplified chimeric antigen receptors and their uses
IL277078A (en) Anti-CD33 chimeric antigen receptors and their uses
PL3436079T3 (pl) Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
IL283144A (en) Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof
EP3797122A4 (en) Anti-ror antibody constructs
IL281428A (en) Chimeric antigen receptor
IL254068A0 (en) Anti-dll3 chimeric antigen receptors and methods of use
IL265219A (en) Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
IL276836A (en) Cd83-binding chimeric antigen receptors
IL285909A (en) Anti-bcma chimeric antigen receptors
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
IL286984A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
IL258502A (en) Chimeric antigen receptors targeted to psca
EP3802615A4 (en) Muc16 specific chimeric antigen receptors and uses thereof
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
PT3286223T (pt) Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
DK3806903T3 (da) Cd79a kimæriske antigenreceptorer
DK3959235T3 (da) Rituximab-resistente kimære antigenreceptorer og anvendelser deraf